Johnson & Johnson (JNJ)vsInnovative Eyewear Inc. (LUCY)
JNJ
Johnson & Johnson
$253.92
+2.13%
HEALTHCARE · Cap: $613.99B
LUCY
Innovative Eyewear Inc.
$0.84
-2.03%
HEALTHCARE · Cap: $7.87M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 2870035% more annual revenue ($97.93B vs $3.41M). JNJ leads profitability with a 21.5% profit margin vs -225.3%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
LUCY
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-86.1%
Fair Value
$141.74
Current Price
$253.92
$112.18 premium
Margin of Safety
+23.1%
Fair Value
$1.43
Current Price
$0.84
$0.59 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Reasonable price relative to book value
Revenue surging 74.5% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Weak financial health signals
Expensive relative to growth rate
Earnings declined 0.9%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -102.4% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : LUCY
The strongest argument for LUCY centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 74.5% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : LUCY
The primary concerns for LUCY are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
JNJ profiles as a mature stock while LUCY is a hypergrowth play — different risk/reward profiles.
LUCY carries more volatility with a beta of 2.74 — expect wider price swings.
LUCY is growing revenue faster at 74.5% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 33/100), backed by strong 21.5% margins. LUCY offers better value entry with a 23.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Innovative Eyewear Inc.
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Innovative Eyewear Inc. (LUCY) stands at the forefront of the smart eyewear sector, merging advanced technology with appealing aesthetics to meet the needs of modern, tech-savvy consumers. Its flagship product line, Lucyd, is designed to provide integrated audio features and seamless connectivity, offering a blend of convenience and style. Firmly focused on enhancing user experience and driving innovation, LUCY is well-positioned to leverage the growing demand for multifunctional eyewear, creating significant growth opportunities in a rapidly evolving market. As the trend towards smart, connected devices accelerates, LUCY’s strategic initiatives to promote its product offerings place it in a strong position for long-term competitiveness and success.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?